新辅助内分泌治疗在中晚期老年乳腺癌治疗中的意义

Value of preoperative endocrine neoadjuvant in the treatment of middle-late breast cancer of elderly women

目的探讨术前新辅助内分泌治疗在中晚期老年乳腺癌治疗中的意义。方法58例老年乳腺癌患者术前服用芳香化酶抑制剂3～9个月并观察疗效，手术后继续服用芳香化酶抑制剂，随访1～5年。结果完全缓解2例（3.45％），部分缓解29例（50．0％），轻度缓解19例（32．7％），无变化5例（8．62％），进展3例（5．18％）。全组随访1～5年，11例在随访期间因本病死亡，6例因其他合并症死亡。结论术前新辅助内分泌治疗在中晚期老年乳腺癌患者中能达到原发病灶和区域淋巴结降期的目的。

Objective To study the curative effect of preoperative endocrine therapy on advanced stage of breast cancer in elderly women. Methods A total of 58 elderly patients with breast cancer were given exemestane for 3～9 month before operation and continually after operation. Follow-up lasted for 1-5 year. Results Complete remission achieved in 2 patients （3.45 %）, partial remission in 29 patients（50%）,minor remission in 19（32.7%）, no change in 5 （8. 62% ）,and aggravation in 3 （5.18%）. Eleven patients died from breast cancer in follow up period, and 6 patients died from other complications. Conclusion Preoperative endocrine therapy for middle-late breast cancer of elderly women could effectively delay or remit the advancement of the tumor.